| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.25 | 2e-05 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.19 | 0.0004 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0005 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.19 | 0.0009 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |